659,730 Shares in Omeros Corporation $OMER Purchased by Corient Private Wealth LP

Corient Private Wealth LP acquired a new stake in Omeros Corporation (NASDAQ:OMER) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 659,730 shares of the biopharmaceutical company’s stock, valued at approximately $6,274,000.

Several other large investors have also made changes to their positions in OMER. BlackRock Inc. purchased a new position in shares of Omeros during the 2nd quarter valued at approximately $57,484,000. Vanguard Group Inc. lifted its holdings in Omeros by 19.9% during the fourth quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company’s stock valued at $68,929,000 after purchasing an additional 666,357 shares in the last quarter. UBS Group AG grew its position in shares of Omeros by 213.5% in the fourth quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock valued at $38,180,000 after purchasing an additional 1,513,893 shares during the period. Geode Capital Management LLC increased its stake in shares of Omeros by 6.3% during the fourth quarter. Geode Capital Management LLC now owns 1,631,350 shares of the biopharmaceutical company’s stock worth $28,026,000 after purchasing an additional 95,979 shares in the last quarter. Finally, State Street Corp raised its position in shares of Omeros by 26.9% during the 4th quarter. State Street Corp now owns 1,573,526 shares of the biopharmaceutical company’s stock worth $27,025,000 after purchasing an additional 333,798 shares during the last quarter. 48.79% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on OMER. Wall Street Zen upgraded Omeros from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Zacks Research lowered Omeros from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. HC Wainwright reissued a “buy” rating on shares of Omeros in a research note on Monday, July 27th. Finally, Weiss Ratings upgraded Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $38.00.

Insider Activity

In other news, Director Thomas J. Cable sold 15,000 shares of the stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $18.45, for a total transaction of $276,750.00. Following the completion of the transaction, the director directly owned 35,067 shares in the company, valued at approximately $646,986.15. This represents a 29.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO David J. Borges sold 10,000 shares of the firm’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $18.95, for a total value of $189,500.00. Following the sale, the chief accounting officer directly owned 5,906 shares of the company’s stock, valued at $111,918.70. The trade was a 62.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 45,906 shares of company stock valued at $850,455 in the last quarter. Insiders own 10.50% of the company’s stock.

Omeros Stock Performance

OMER stock opened at $18.61 on Monday. The firm has a market cap of $1.35 billion, a PE ratio of 14.54 and a beta of 2.54. The firm’s 50 day moving average price is $12.64 and its 200-day moving average price is $12.03. Omeros Corporation has a one year low of $3.94 and a one year high of $19.65.

Omeros (NASDAQ:OMER) last issued its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.29. The business had revenue of $28.53 million during the quarter, compared to analysts’ expectations of $12.69 million. Equities research analysts predict that Omeros Corporation will post -0.37 EPS for the current fiscal year.

Omeros Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.